Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06027996 · ClinicalTrials.gov registry record · NA
Melodi Matrix™ in Breast Reconstruction
A NA study of Breast Reconstruction, sponsored by Melodi Health.
- Recruiting
- Registry status
- NA
- Development phase
- 702
- Enrollment target
- 10
- Study locations
NCT06027996: Recruiting NA study of Breast Reconstruction, sponsored by Melodi Health.
NCT06027996 is a NA study of Breast Reconstruction that is actively recruiting participants, run by Melodi Health. The registered enrollment target is 702 participants, above the 355-participant average among 18 other Breast Reconstruction trials with a reported enrollment target (98% higher). The trial reports 10 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06027996, a NA study of Breast Reconstruction, is actively recruiting participants, sponsored by Melodi Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 702 participants
- Enrollment target
- 10
- Study locations
Study Summary
Prospective, multicenter, randomized, controlled trial evaluating the safety and effectiveness of an absorbable antibacterial matrix device in two stage prepectoral alloplastic breast reconstruction.
Primary Outcome
Key local complications
Conditions Studied
Interventions
- DEVICE Absorbable Antibacterial Matrix
Study Locations (10)
California
- Stanford University - Palo Alto
Michigan
- University of Michigan Health - Ann Arbor
Minnesota
- Mayo Clinic - Rochester
New York
- Northwell Health - Staten Island
Ohio
- The Ohio State University - Columbus
Pennsylvania
- UPMC - Pittsburgh
South Carolina
- Medical University of South Carolina - Charleston
South Dakota
- Monument Health - Rapid City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 702 participants |
| Start Date | 2024-08-09 |
| Est. Completion | 2028-06 |
| Phase | NA |
What NCT06027996 shows while recruiting
NCT06027996 is an interventional study that assigns participants to a tested intervention. The registered 702 participants enrollment target is mid-sized for trials with a published cap, above the 355-participant average among 18 other Breast Reconstruction trials with a reported enrollment target (98% higher).
The record links to 1 condition, with Breast Reconstruction appearing as the primary indexed condition, and to 1 intervention - of which Absorbable Antibacterial Matrix is the first listed.
NCT06027996 lists 10 locations in 10 states (California, Michigan, Minnesota).
Frequently Asked Questions
What is clinical trial NCT06027996 about?
NCT06027996 is a clinical study titled "Melodi Matrix™ in Breast Reconstruction". Prospective, multicenter, randomized, controlled trial evaluating the safety and effectiveness of an absorbable antibacterial matrix device in two stage prepectoral alloplastic breast reconstruction.
What is the current status of trial NCT06027996?
This trial is currently recruiting. It is a NA study. The enrollment target is 702 participants. The study started on 2024-08-09. Estimated completion is 2028-06.
What conditions does trial NCT06027996 study?
This clinical trial studies the following conditions: Breast Reconstruction.
What interventions are being tested in trial NCT06027996?
The interventions under investigation include: Absorbable Antibacterial Matrix (DEVICE).
Who is sponsoring clinical trial NCT06027996?
This trial is sponsored by Melodi Health, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06027996 being conducted?
This trial has 10 study locations across California, Michigan, Minnesota, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Reconstruction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06027996's enrollment target sits among peer trials
702 4th of 18 higher than 15 of 18 other Breast Reconstruction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Reconstruction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study on Pain After Breast Reconstruction
RECRUITING · NA
-
A Comparative Analysis of REVOLVE, LipoGrafter, and Viality in Autologous Fat Grafting During Breast Surgery
RECRUITING · NA
-
Impact of Pectoral Versus Paravertebral Blocks on Pain and Physical Well-Being in Implant-Based Breast Reconstruction
RECRUITING · NA
-
Pulsed Lavage in Implant-Based Breast Reconstruction
RECRUITING · NA
-
SAVE Trial: SAfe Opioid Use Video Education
RECRUITING · NA
-
Acellular Dermal Matrix Investigation in Breast Reconstruction
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05796687 · 704 participants · NA
Evaluation of My Future Self, an New Teen Pregnancy Prevention Group Intervention for Youth in Non-traditional Settings
- NCT06350734 · 704 participants
Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study
- NCT00900419 · 700 participants
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
- NCT01804686 · 700 participants · Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI